Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5

ktn-uk.org/global-alliance
Innovate UK KTN Global Alliance in
collaboration with Foreign
Commonwealth and Development Office
(FCDO)
26th November 2021
Horizon Europe –
Tackling Disease and
AMR Webinar
https://ktn-uk.org/news/horizon-europe-work-programme-funding-calls-
health/

Welcome and housekeeping
• Due to the large number of people registered all
participants will be muted.
• After testing your speakers, please do remember to
connect your audio by using the “Join Audio” icon at the
bottom left of the screen or dial in via phone using the
number provided in the joining instructions.
• If you have any technical problems, please use the chat to
seek advice from the host (Jess Dobbyne).
• Questions and Answers Please also use the chat function
• Please use the chat function to introduce yourself, please
note due to GDPR we cannot share the chat. Capture
what you need
PLEASE NOTE – THE WEBINAR IS BEING RECORDED
The recording and slides will be made available via the KTN website
Welcome to our Horizon Europe event series in
collaboration with FCDO and Innovate UK
Horizon Tackling Disease and AMR
It’s World AMR week!

The Agenda
• 09:30 – Introduction & Aims of the Day | Jane Watkins, KTN & Frances Wood , Regional Director for the UK
Government Science and Innovation Network covering Europe, Russia and Turkey, FCDO
• 09:40 – Introduction to Horizon Europe | Jane Watkins, KTN
• 09:50 – Overview of Health work programme (2022 calls under Destination 3. Tackling diseases and
reducing disease burden) | Kay Duggan-Walls, Health Research Board (NRB), Ireland
• 10:05 – Overview of the JPIAMR call | Laura Plant, JPIAMR Secretariat, Swedish Research Council
• 10:20 – Q&A
• 10.30 BREAK
• 10:40 – Case study | Anita Hogg, Medicines Optimisation Innovation Centre (MOIC)
• 10:50 – Getting started and finding the right partners? | Jo Frost, UK Health NCP for Industry, Innovate UK
• 11:15 – Pitching Sessions
• 12:30 – Lunch
• 13:00 – Networking via Meeting Mojo & NCP Surgery

• NCP 1:1 meetings from 1-2.30pm (GMT)
National Contact Point Contact Country
Ewa Szkiladz Narodowe Centrum Badań i Rozwoju, Poland
Valentina Albarani
Union Wallonne des Entreprises (UWE), Belgium
(Wallonie)
Živilė Ruželė Research Council of Lithuania (LMT), Lithuania
Doris Bell
Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR),
Germany
Sasha Hugentobler Euresearch Network Office, Switzerland
Patricia McCrory QUB, Northern Ireland
Kay Duggan-Walls Health Research Board, Ireland (available 1-1.45pm)
Sofia Magdalena Anderholm Strand The Research Council of Norway, Norway
Joanna Frost Innovate UK UKRI, UK
The link for people to find NCPs in other countries is
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp/.

Networking and Connecting – Pitches Instructions and Running Order
• The pitch presentations will begin at 11.15 am.
• We will load and control your slides.
• We will unmute you to allow you to present your slides. Please ensure you have
connected your audio and your microphone before the pitch sessions begin. You can test
your speaker and microphone by clicking the arrow next to the microphone. This will bring
up a dropdown of options, including ‘Test speaker & microphone.’
• The pitches will run in alphabetical order of organisation.
• You will have opportunity to pitch for 2 minutes.

Pitch Running order
Organisation Speaker
Aston University Jonathan Cox
Aquarius Population Health Limited Katy Turner
Biocrucible David G Brooks
Centre of Postgraduate Medical Education Damian Gawel
Genemill J. Enrique Salcedo-Sora
IBIMA Aitor Rando Rodán
IBISS Ivana Stojanović
Imperial College London Leonid Chindelevitch
Medicines Discovery Catapult Helen Bright
Open University of Israel Ofer Reany
Oslo Hospital University James Booth
Oxford Vacmedix William Finch
Scotland’s Rural College Nicola Holden
University of Aberdeen Soumya Palliyil
University of Kent Jennifer Hiscock
University of Liverpool Dr Qibo Zhang

Networking and Connecting – Meeting mojo
• This is a separate platform to Zoom
• You can organise 1:1 meetings with other registered users
• You will be able to create your profile, search other users’ profiles and book video
chat meetings via the platform.
• You can search by organisation, by individual or by key word.
• Don’t forget to confirm your requested meetings!
• https://he-amr.meeting-mojo.com/
• Opportunity to network this afternoon. Will remain open until the for 1 week (Close 3rd
December) we can keep going if active!

Introduction and Aims of the Day
Frances Wood - Regional Director for the UK Government Science and
Innovation Network covering Europe, Russia and Turkey, FCDO

Horizon Europe
Jane Watkins
European Programmes
Innovate UK KTN

• Funding programmes created by the European Union/European Commission to
support and foster research and innovation
• Began in 1984 and each last for 7 years and align to the EU’s Multiannual Financial
Framework (MFF)
Horizon 2020
• The previous Framework Programme (FP). It began in 2014 and had its last call for
proposals in 2020. Total budget for Horizon 2020 was ~ €80bn
Horizon Europe
• The 9th FP and successor to Horizon 2020 will run from 2021 to 2027
• €95B total budget - Work Programmes are available
European Framework Programmes
The UK has agreed to Associate to Horizon Europe

UK ‘Association’means continued UK participation
The UK has agreed to Associate to Horizon Europe
11
•UK entities will have equivalent participation rights to those from Member States
•UK entities can lead projects as coordinators
•UK has continued access to Horizon Europe research and innovation funding, infrastructure and markets
•Able to access funding from all parts of the Programme including the ERC (European Research Council), MSCA (Marie Skłodowska-Curie
Actions), Partnerships, the EIT (European Institute of Innovation and Technology), the direct actions of the JRC (Joint Research Centre).
The UK will be an associate to the COST programme and to EURATOM and ITER. Can access the majority of the EIC (European
Innovation Council) the except the EIC Accelerator equity fund
•Work programme level exclusions only in exceptional and justifiable cases (e.g., some Defence & Security)
•Participation and influence on programme governance structures (e.g. programme committees)
•UK experts can continue to take part in peer review (register as an expert here)
•The ‘Associated Countries’ concept is not new - Horizon 2020 had 16 Associated Countries including Israel, Norway and Turkey

EU confirmation of UK participation
European Commission Q&A on the UK’s Participation in Horizon Europe
UK Association
“UK participants will have the same rights as
EU participants…”
“UK entities are eligible for funding at the
same rates and under the same
conditions”
“They can lead project consortia”

Size of the prize – Horizon 2020 UK stats
(EU average 11.91%)

• €95.5bn total funding agreed for 2021-2027
• NB budget figures exclude UK and other Associate Country contributions
• Canada, Japan, Australia etc. Interested status (TBC)
Horizon Europe structure

• Research and innovation actions (RIA)
• Innovation actions (IA)
• Coordination and support actions (CSA)
• RIA – Research and Innovation Actions – up to 100% funding rate. Page limit usually 45 pages
• IA – Innovation Actions – up to 70% funding rate (except non-profit, 100% applies). Page limit usually 45 pages
• CSA – Coordination and Support Actions – up to 100% funding rate. Page limit usually 30 pages
Main Types of
Project
Main Project Types
• Excellence
• Impact
• Quality and Efficiency of implementation
Award Criteria

Why
participate?
High funding rate: up
to 100% of eligible
costs
The only guaranteed
and predictable
funding for certain
sectors
No artificial
constraints
(consortium size,
budget allocation to
non-industrials...)
Access to cutting
edge technologies,
infrastructure &
talent
Increased visibility at
EU & global level
Build domestic and
international
partners/customers
Solving global grand
challenges through
collaborative R&D
Influence standards,
regulations and
research policies
Creating UK jobs,
growth and stronger
supply chains

Q&A Session

BREAK

Networking and Connecting – Meeting mojo
• This is a separate platform to Zoom
• You can organise 1:1 meetings with other registered users
• You will be able to create your profile, search other users’ profiles and book video
chat meetings via the platform.
• You can search by organisation, by individual or by key word.
• Don’t forget to confirm your requested meetings!
• https://he-amr.meeting-mojo.com/
• Opportunity to network this afternoon. Will remain open until the for 1 week (Close 3rd
December) we can keep going if active!
• Networking cards (if you haven’t pitch there is also opportunity to share your
expertise looking for partners or joining a consortium
• https://drive.google.com/drive/folders/1808EnJFpxSAtz8tqdV9wxcTruSWuuyod?usp=s
haring

CLOSE
Thank you

Horizon Europe Tackling Diseases and Antimicrobial Resistance(AMR)
Cluster 1 Destinations 3 and 5
Kay Duggan-Walls, NCP Horizon Europe, Cluster 1 Health

Destination 3 - Expected Impacts
Tackling diseases and reducing disease burden
Expected Impacts
• For health the burden of disease in the EU and worldwide will be reduced through effective disease
management, including development and integration of innovative diagnostic and therapeutic approaches,
personalised medicine approaches, digital and other people-centre solutions to health and care
• Patients should be diagnosed early and accurately and receive effective cost-efficient and affordable treatment,
including for rare diseases
• Premature mortality from non-communicable diseases reduced by one third by 2030
• Healthcare systems should be better prepared to respond to health emergencies
• Patients and citizens should be knowledgeable about disease threats, involved and empowered to make and
shape decisions for their health

Destination 3 Topics
Topics by 'Destination' or 'Expected Impact' 2022 Instrument Single Stage
or Two-stage
No. Proposals
to be funded
Destination 3. Tackling diseases and reducing disease burden
*Call HORIZON-HLTH-2022-DISEASE-06-two-stage – Tackling diseases (Two
Stage - 2022)
HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of
the next generation immunotherapies for diseases or disorders with unmet
medical need
60 RIA Two-Stage 10 (€6M)
HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the
next generation of vaccines
HORIZON-HLTH-2022-DISEASE-06-04-two-stage: Development of new
effective therapies for rare diseases
*Call HORIZON-HLTH-2022-DISEASE-07 – Tackling diseases (Single Stage -2022)
HORIZON-HLTH-2022-DISEASE-07-02: Pandemic Preparedness 10 RIA Single Stage 3 (€3M) Opening
12 Jan
HORIZON-HLTH-2022-DISEASE-07-03: Non-communicable diseases risk
reduction in adolescence and youth
25 RIA Single Stage 8 (€3M)

Destination 5 – Expected Impacts
Unlocking the full potential of new tools, technologies & digital solutions for a healthy
society
Expected Impacts
• Contribute to Europe’s:
• Scientific and technological expertise and know how
• its capabilities for innovation in new tools
• Its ability to take-up, scale-up and integrate innovation in health and care
• Enable researchers, innovators and healthcare providers to use health data and AI
supported decision-making in a secure ethical acceptable and trust worthy manner
• Citizens should benefit from
• Safer, more efficient, cost effective and affordable tools, technologies and digital
solutions
• For effective personalised disease prevention, diagnosis treatment and monitoring for
better patient outcome and well-being
• In particular through increasingly shared health resources

Destination 5 Topic
Topics by 'Destination' or 'Expected Impact' 2022 Instrument Single Stage
or Two-stage
No. Proposals to
be funded
Destination 5. Unlocking the full potential of new tools, technologies &
digital solutions for a healthy society
Call HORIZON-HLTH-2022-TOOL-11 – Tools and technologies for a healthy
society (Single Stage - 2022)
HORIZON-HLTH-2022-TOOL-11-02: New methods for the effective use of real-
world data and/or synthetic data in regulatory decision-making and/or in
health technology assessment
35 RIA Single Stage 5 (€7M)

Contact
Kay Duggan-Walls, MSc
NCP Health
Health Research Board
kdugganwalls@hrb.ie
Tel (01) 2345 187
085 8868183

www.jpiamr.eu twitter.com/JPIAMR facebook.com/JPIAMR
JPIAMR: Supporting
Transnational Research
Laura Plant
Senior Research Officer
JPIAMR Secretariat

JPIAMR: A global organisation
The European Commission
(DG Research) is a full non-
voting member
28 member countries
Coordinates AMR research
and funding
One Health
perspective
International collaborative platform

SRIA: Strategic Research
and Innovation Agenda
Understanding and preventing the transmission of antimicrobial
resistance
Transmission
Discovery of new antimicrobials and therapeutic alternatives, and
the improvement of current antimicrobials and treatment regimens
Therapeutics
The role of the environment in the persistence, selection and spread
of antimicrobial resistance
Environment
Optimisation of surveillance systems to understand the drivers and
burden of antimicrobial resistance in a One Health perspective
Surveillance
Development and improvement of diagnostics to improve the use of
antimicrobials and alternatives to antimicrobials
Diagnostics
Investigation and improvement of infection prevention and control
measures in One Health settings
Interventions

JPIAMR: A global One Health AMR Research Funder
23%
31%
11%
5%
9%
21%
Therapeutics
• Discovery of new antimicrobials and
therapeutic alternatives
• New target identification
• Repurposing of drugs
Transmission
• Transmission mechanisms and routes
• Strategies to inhibit or reduce AMR
transmission
• Risk assessment
Surveillance
• Improvement of Surveillance
tools and technologies
• Standardisation of methods
Diagnostics
• New rapid diagnostics and
point-of-care techniques
• AMR detection in multiple
reservoirs
Interventions
• Interventions for infection
prevention and control measures
Environment
• Transmission routes in environment
• Surveillance of non-human AMR reservoirs
(wildlife, wastewater)

Researcher Location
Overview of JPIAMR supported research
>100 M€
Total Investment
1313
Researchers
› From 71 different countries
Networks
Projects
118
80
38
32 LMICs involved
80 researchers from LMICs
25 research project and
networks with LMIC elements in
their research scope
One Health perspective
Projects with
One Health aspect
38%

Roadmap of Actions 2019-2024

JPIAMR Roadmap 2021-2024
JPIAMR Activity 2021/22 2022/23 2023/24
Research Calls Transmission and Interventions
ONGOING: One Health
interventions to prevent or
reduce the development and
transmission of AMR
Therapeutics
IN DEVELOPMENT: Optimising
existing drugs or drug
combinations for the prevention
and treatment of infections
Diagnostics and Surveillance
Development of innovative,
digital technologies for collection
of microbiological and antibiotic
data
Network Calls Diagnostics and Surveillance
IN DEVELOPMENT: Network Call
Interventions
Building Bridges between One
Health areas to implement
interventions

Call for Research Projects Call for Research Networks
Nature of the call Project calls support multi-national
translational research collaborations for AMR
research scientists that includes (but not limited
to) basic research, pre-clinical and phase 1
clinical trials
Networks of AMR experts, scientists and policy
makers to enhance resource alignment, capacity
building and maximise existing and future
efforts to combat AMR through multinational
collaborations
Expected outputs and outcomes Research findings White papers, views, guidelines, and/or best
practice frameworks, and others
Application process 2-stage application 1-stage application
Size of the consortium 3-7 researchers from at least 3 JPIAMR (or
fundable) countries
Typically 15 partners from at least 10 different
countries
Funding amount and details • Coordinator and partners funded by their
national funding agencies
• Funding amount according to national
guidelines
• Coordinator is funded by their national
funding agency
• Funding amount 50-200k€ (call dependent)
JPIAMR funding mechanisms

14th JPIAMR Call
Disrupting Drug Resistance Using
Innovative Design (DRUID)
..
• Participating countries: Belgium (FWO, FNRS), Canada (CIHR), Czech Republic (MEYS), Estonia
(ETAg), France (ANR), Germany (BMBF), Hungary (NKFIH), Israel (CSO-MOH), Italy (FRRB, It-
MoH), Latvia (VIAA, LZP), Lithuania (RCL), Moldova (ANCD), Poland (NCN, NCBR), Spain (AEI,
ISCIII), Sweden (SRC, SIDA, Vinnova), Switzerland (SNSF), United Kingdom (UKRI-MRC, UKRI-
BBSRC, UKRI-EPSRC)
• Estimated call budget: € 17 million
• Call opens: January 11 2022 (planned)
• Information: www.jpiamr.eu and @jpiamr

14th JPIAMR Call
• Aim: to improve the treatment of bacterial and fungal infections (including co-infection) and/or
the prevention of the emergence/spread of resistance in humans, animals or plants through
the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of
drugs and plant protection agents.

14th JPIAMR Call
• Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents
under pre-clinical and/or early clinical development, and should address at least one of the
following topics:
• Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications
(including hit to lead optimisation)
• Drug/plant protection agent repurposing;
• Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including
therapeutic vaccines);
• Design and implementation of new strategies (including optimisation of drug doses) for improved application,
efficacy and delivery of single or combinations of antimicrobials;
• Design and implementation of innovative tools, including novel chemistry and/or new materials for improved
application, efficacy and delivery of antimicrobials.

14th JPIAMR Call
• Proposals can focus on one or more of the three “One-Health” settings:
• Human Health
• Animal Health (including wildlife, livestock, fishes, and companion animals)
• Plants (including trees and crops)
• Participation of end-users, stakeholders and companies is encouraged.
• The following sub-topics are out of scope of the call:
• Antiviral and antiparasitic agents
• Discovery and/or screening of new compounds, new vaccines and/or new targets
• Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in
evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)

14th JPIAMR Call
Webinar for applicants
• 25th of January 2022
• Present the call and the partner search tool
• Representatives from funders participating in the call will answer questions live
Partner Search Tool
• A match-making tool to facilitate networking and the creation of consortia
• Will be open on the day of the launch of the call
• The tool can be consulted for several purposes:
• Partner looking for project: As individual researcher or a representative of a lab or research team, searching for
a project to join.
• Project looking for partner: If you want to build a consortium around an existing project and want to find
partners for your project ideas.

15th JPIAMR Call
Diagnostics and Surveillance Networks
• Participating JPIAMR - ACTION members (to date): Egypt (ASRT), Estonia (ETAg), France
(ANR), Italy (It-MoH), Lithuania (RCL), Moldova (ANCD), Netherlands (ZonMw), Norway
(RCN), Spain (ISCIII), Sweden (SRC), United Kingdom (UKRI-MRC)
• Funding: € 50,000 per Network
• Call opens in April 2022
• Information: www.jpiamr.eu and @jpiamr

15th JPIAMR Call
• Aim: to assemble networks of leading experts and stakeholders with an intent to facilitate the
development, optimisation and use of diagnostic and surveillance tools, technologies and
systems.

15th JPIAMR Call
• Networks should work towards the conceptualisation of ideas in order to provide white
papers, guidance documents and/or best practices/roadmaps and evidence frameworks to
identify key questions to be addressed and/or potential solutions to overcome barriers to
enhanced surveillance and advanced diagnostics to reduce the burden of AMR.

15th JPIAMR Call
• 22 March 2022 – Detailed pre-announcement text available
• 12 April 2022 – Call opens
• 28 April 2022 – Webinar for applicants
• 14 June 2022 – Proposal deadline

• Register on the partner search tool when the call opens
• Participate in the call webinars
• Subscribe to JPIAMRs newsletter
• Keep updated on national rules via the JPIAMR call webpage and any additional national
funding agency webpages
What can you do to prepare?

For more information:
Subscribe to the JPIAMR newsletter
Follow JPIAMR on social media
Follow any updates from national agencies
Information will be available early in 2022.

European funding…
Hints and tips for success
Anita Hogg
Lead, Medicines Optimisation
Innovation Centre (MOIC)

MOIC tips
1. Finding partners
2. Identifying call topic
3. Writing proposal
4. Budget
5. Grant agreement partnership (GAP)
signing and grant agreement

1. Finding partners….create
networks
Denmark Norway Ireland Sweden UK Netherlands
Egypt Estonia
Jordan New
Zealand
Palestine Poland
Spain

3. Writing proposal
Varies depending on
consortium – be flexible!
Maximise lead in time,
GANTT chart, PIC,
populate
Partner commitment up
front - accountable!
Dates in diaries (weekly!)
& clear actions
Strong consortium
Know grant requirements
& align

Writing proposal
Strong consortium
lead and WP leads
Align partners
expertise with work
packages
European hot topics
(medicines in pregnancy
and breastfeeding)
Differences in
structures, policy and
practice
Clearly define
deliverables that
you can deliver!
Terminology
(medicines optimisation, medicines
management, pharmaceutical care,
clinical pharmacy)

4. Budget
Consult local finance team early*
Maximum available?
Funding level (eg 100%)?
Eligible costs?
PPM - number of ways to calculate
Negotiation within consortium
Be REALISTIC
*No research office eg SME contact NI/UK Contact Point for steer

5. Grant agreement partnership
and signing agreement

5. Grant agreement partnership
and signing grant agreement
COMPLEX
Difficult for
MOIC (new)
Consider at
proposal stage
Good
governance
LEAR
LSIGN
FSIGN

Keep going…..
Review feedback &
connect with partners
Resubmit/repurpose for
another grant

Where are we now?
• MEDSAFE
• Interested in other
Cluster 1 (Health) calls
• April 2022

Final tips…
• Draw on experience of others
• Seek help if required
• Start small, partner well -
progress
• Very competitive – don’t be
put off (some only fund 5!)
• High score but not funded
• GO FOR IT!

moic@northerntrust.hscni.net
@moicni
www.linkedin.com/company/moic/
www.themoic.hscni.net

Getting started and finding partners
26Nov2021
JoFrost–UKHorizonEuropeNationalContactPoint(NCP)
(ncp-health@innovateuk.ukri.org)
Slides happily shared
NCPs in other countries
Please sign up our UK newsletter here for the latest Horizon Europe health
funding opportunities news

Agenda
2
• National Contact Points
• UK Government ‘Pump Priming’ funding
• Project types
• Eligibility criteria, Associated Countries, International participation
• Building a consortium
• Funding partners
• Tips

What is a National Contact Point (NCP)?
NCP
Businesses
RTOs
Academia
UK Gov
EU
Commission
Global R&I
network
UK NCP network: Team of sector specific public servants whose role it is
to provide free support to UK participants to Horizon Europe
International NCP network: support in Europe and the rest of the World
NCP services vary in each country/sector, but typically include:
Jo Frost
UK Health NCP for industry
Informing, awareness raising – on Horizon Europe and other
EU programmes
Assisting, advising and training – to improve the quality of
Horizon Europe proposals
Signpos6ng and coopera6on – direct to relevant support and
work with each other to support consor<um development
Please sign up for our newsletter here for the latest Horizon Europe health
funding opportunities news

New: UK Government ‘Pump Priming’ Funding
4
• For UK organisations and their consortia (in any eligible country) preparing Horizon Europe
proposals
• Applicants will need to identify a specific upcoming call (in Pillar II) as the focus of their proposed
collaboration with the goal of submitting an application to that upcoming call, building on this pump
priming funding.
• Up to £10,000 available per proposal
• Next deadline 8 Dec then every 2 weeks (until all call budget is used)
• Call website
• LinkedIn post – please read comments thread for extra info on how funding can be used/who can be funded
The pump priming call is run by The British Academy, the Science & Innovation Network in Europe, UK Research and
Innovation and KTN with the support of The Academy of Medical Sciences & the Royal Academy of Engineering

Main Project Types (in Health Cluster)
5
Research and innovation actions (RIA)
• Activities aiming primarily to establish new knowledge or to explore the feasibility of a new or improved technology,
product, process, service or solution.
• May include basic and applied research, technology development and integration, testing, demonstration and validation
on a small-scale prototype in a laboratory or simulated environment.
Innovation actions (IA)
• Activities directly aimed at producing plans and arrangements or designs for new, altered or improved products,
processes or services
• Possibly including prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.
Coordination and support actions (CSA)
• Activities contributing to the objectives of the Horizon Europe Programme, excluding R&I activities (with some exceptions
– see the General Annexes to the Work Programme)
• Pre-commercial procurement actions (PCP)
• Public procurement of innovative solutions actions (PPI)
From the Work Programme 2021-2022 General Annexes

Eligibility
Eligibility for funding is usually (unless otherwise stated in the call):
• Any type of legal entity established in EU Member State (MS) or ~18 Associated Countries (AC)
• Legal entities from ~115 Low & Middle Income Countries (LMICs) if country listed here
• International European research organisations
• You can also get funding for organisations in other higher income countries occasionally:
• If it is specified in your call topic, or
• If their participation is essential for the project.
• US organisations funded in Health Cluster only (✔RIA and IA ❌CSA unless mentioned in call topic)
Eligibility for participation is usually (unless otherwise stated in the call):
• legal entities from outside EU MS/AC (known as ‘third countries’) can often participate too, although
they would normally need to fund their own participation (unless one of the above exceptions applies)

High income countries outside Europe/AC
For higher income countries outside of Europe (which are not associated countries):
• there are often national contact points who will be able to advise if any local funding is available to enable
them to participate. Sometimes the local funding is available to allow their researchers to participate in all
calls, sometimes just for specific call topics, and sometimes funding is not available locally.
• for the previous programme, Horizon 2020 the European Commission has some “country page” specific
guidance (e.g. Brazil, India and China) with info and contacts. These documents are not yet available for
Horizon Europe, but there is some info here.
Switzerland:
• For 2021 and 2022 calls, Swiss entities can participate in collaborative projects (including RIAs
and IAs) as a Third Party ‘Associated Partner’
• Funding provided by Swiss government: Financial Guarantee for 2021 and 2022
• Dedicated website including FAQs: https://www.horizon-europe.ch
• You can find templates and checklists on how to add an Associated Partner and its budget and
other related issues on this website

Consortia Size
Minimum consortium size
• Collaborative projects: Usually a consortium must have a minimum of 3 independent legal entities, each
established in different EU Member States (MS) or Associated Countries (AC), with at least 1 of them
established in a MS
• Coordination & Support Actions: One or more legal entities, which may be established in a MS, AC, or in
exceptional cases and if provided for in the specific call conditions, in another third country.

What do ideal partners look like?
• Expert in their area
• Enthusias.c and commi3ed
• Responsive to coordinator’s requests, able to communicate well (think about languages too?)
• Trustable

How to start building a consortium?
• What expertise is needed for the project? (Read the call topic very carefully)
• Which sectors and disciplines are needed? (Academia, Industry, stakeholders, patient groups…?)
• Are there people you have worked with before or know with suitable expertise? Friends of
friends?
• What expertise is still needed? Where might you find good partners with this expertise?
• How will people/organisations be involved? Partners? Advisory groups? To feed in/disseminate to?
• Think about ‘European Added value’
• Good to have some partners/orgs. with EU/collaborative experience (Especially as coordinator?)

Formal consortium building mechanisms
Some also have other tools/partner databases (e.g. EEN/EDGE, Innovative Medicines/Health Initiative
Participant portal – Every topic has a ‘Partner Search’ function where you can upload your profile
and review others that have done so
Brokerage events – European Commission, Enterprise Europe Network, UK’s KTN, NCPs from around
Europe, Technology Platforms etc will virtual hold events with e.g., Meeting Mojo, B2Match
Partner Search – under the How to participate tab on the EU funding and tenders portal where you
can search for past projects and organisations
Horizon Europe 2022 Health Calls – Brokerage Event on 29 Oct – website still open
CORDIS – a more useful way of finding past projects and participants and allows you to contact them
Searching the formal consortium building
mechanisms is a bit like looking for a
needle in a haystack – they all look like
needles so finding the ones for you can
be difficult

2022 Health Calls – Infoday and Partnering Events
• 28 Oct 2021: European Commission Health Calls infoday on 28 Oct (presentations + Q&A avail to watch)
• 29 Oct 2021: Main partnering event for Health 2022 calls (site live until end Jan 2022) organised by Health
NCPs, European Commission, EEN
• On the marketplace tab you can
see who have entered info for each
topic – you will need to turn on the
‘project cooperation’ toggle, then can
tick topics

2022 Health Calls – Infoday and Partnering Events
• On the participants tab you can also see which organisations are interested in each call topic and can also
search by country or organisation type (may include some organisations extra not on the ‘marketplace’ tab)
• Joint Programming Initiative AMR (JPI AMR) 2022 Call on Therapeutics ‘Disrupting drug resistance
using innovative design’
• 25 Jan 2022 Webinar and presentation on partner search tool

EU Participant Portal – Call Topic pages
Demo
Example…

Demo
UKRI webpage with guidance on how to use the partner search tool
EU Participant Portal – Call Topic pages

CORDIS https://cordis.europa.eu/search/en

Demo: https://cordis.europa.eu/project/id/755667
CORDIS https://cordis.europa.eu/search/en

Cluster 1 (Health) NCP partnering form
Partnering form
• Can be circulated at any time
• Contact your NCP for a copy:
• MRC UK Health NCP for academia
(ncp@mrc.ukri.org)
• Jo Frost UK Health NCP for industry
• NCPs in other countries

The best ways to form winning teams
Being an effective networker is much more useful than submitting a profile into a portal and
awaiting contacts. Don’t wait to be invited to the party, push yourself forward
• Use your existing professional networks – if you don’t know who the sector leaders are in
Europe then you should find out
• Use Linked In to connect to people from possible consortium partners
• Search CORDIS for previous, related projects and contact the participants. All projects must
disseminate their results and often hold workshops, etc.
• Join the relevant networks, associations and partnerships
• Be an active member – say ‘hi’ when you join the virtual room. Ask questions, support
others’ opinions, act as if you are already well known to all in the virtual room
• Volunteer to draft working papers, take notes, send in useful information – be helpful
• Speak up at workshops – demonstrate Thought Leadership
• Show that you would be a valuable partner for collaborative projects and that without
you they won’t win – you have the secret sauce that is necessary for their success

What constitutes a winning consortium?
One that can deliver the expected outcomes within the stated scope and budget (and give the evaluators
confidence that they can)
There is no ‘typical’ or ‘model’ consortium structure/membership, it depends what is needed for the call
topic.
• Any type of organisation can be funded by Horizon Europe. It is common to see universities, big business,
small business, research and technologies organisations, local/national authorities, patient groups,
charities, policy makers all within the one consortium.
Useful to include exploitation partners – someone who is going to take the outputs of the project and
actually implement them (e.g. in policy/industry/hospitals/patient care/civil society/cultural and creative
sectors) to show immediate impact. Many Health cluster call topics mention involving patient groups too.
Useful to include the end user community, possibly as an advisory board or associate partners (not direct
beneficiaries but costs e.g. travel can be included in ‘other costs’), again to demonstrate their involvement in
the design of your project so it suits their needs, and also to show a route to your project having impact.

Hints and Tips – Building a consortium
Quesons to think about:
Who has the best experse/reputaon?
Who should you approach to be part of a consorum?
Not everyone has to have the same size role
Don’t include partners because you think it will look good or to pad the proposal out - each partner should
have a clear and deﬁned purpose.
Have a good balance of countries – more than ~30% if the budget going to one country might be of concern
to the evaluators

Thank you
Slides happily shared

Pitching session

Networking and Connecting – Pitches Instructions and Running Order
• We will load and control your slides.
• We will unmute you to allow you to present your slides. Please ensure you
have connected your audio and your microphone before the pitch sessions
begin. You can test your speaker and microphone by clicking the arrow next to
the microphone. This will bring up a dropdown of options, including ‘Test
speaker & microphone.’
• The pitches will run in alphabetical order of organisation.
• You will have opportunity to pitch for 2 minutes

Pitch Running Order
Organisation Speaker
Aston University (UK) Jonathan Cox
Aquarius Population Health Limited (UK) Katy Turner
Biocrucible (UK) David G Brooks
Centre of Postgraduate Medical Education (PL) Damian Gawel
COAD University of Queensland, Australia Mark Blaskovich
Genemill (UK) J. Enrique Salcedo-Sora
IBIMA (ES) Aitor Rando Rodán
IBISS (RS) Ivana Stojanović
Imperial College London (UK) Leonid Chindelevitch
Medicines Discovery Catapult (UK) Helen Bright
Open University of Israel (IL) Ofer Reany
Oslo Hospital University (NO) James Booth
Oxford Vacmedix (UK) William Finch
Scotland’s Rural College (UK) Nicola Holden
University of Aberdeen (UK) Soumya Palliyil
University of Kent (UK) Jennifer Hiscock
University of Liverpool (UK) Dr Qibo Zhang

Mycobacterium abscessus
• Multidrug resistant: no truly
effective treatment regime
• Prevalent in Cystic Fibrosis
patients
• We have a large bank of clinical
isolates across all 3 subspecies
• Combinations including β-
lactam/β-lactamase inhibitor
combinations
Antibiotic Discovery at Aston University
Mycobacterium tuberculosis
• Non-replicating persistent Mtb
drug discovery
• Currently no drugs for treating
latent TB, only active
• Developed the first
physiologically relevant assay
for NRP-TB drug screening
Dr Jonathan Cox, j.a.g.cox@aston.ac.uk
Business
collaborations
ESKAPE and
WHO Priority
Pathogens

Proposed Approach
We propose to support bids as a partner, by providing qualitative and quantitative insight, health
economics and modelling as applied to infectious diseases and diagnostics including AMR.
We can address how to understand the burden and unmet need of AMR from a disease,
diagnostic and system perspective, including One health.
We anticipate partnering with academic, industry, charity, healthcare providers and
other partners to provide our specialist expertise in generating evidence broadly around health
economics of interventions for AMR.
Organisational Capabilities
We bring expertise in health economics and
modelling applied to infectious diseases and
diagnostics and AMR. We provide flexible, dynamic
and high-quality solutions.
We generate evidence to inform and support
rational decision-making and policy in healthcare.
We support the planning, evaluation and
implementation of better and more efficient
healthcare to improve patient care and outcomes.
Experience
• Multidisciplinary team works across sectors and disease areas
• Use creative approaches in seeking solutions
• Flexible and responsive to our partners’ needs, and champion collaborative working and close
partnerships to deliver true value when exploring challenges
• Experience of being co-applicant on successful grant-funded projects (SBRI, Innovate UK,
NIHR, etc.)
• Extensive experience in AMR, including numerous publications and contributor to the O'Neill
Review.
Administrative Information
We plan to be a partner
Horizon Europe Tackling Diseases and
Antimicrobial Resistance (AMR)
Aquarius Population Health Limited
Unit 29 Tileyard Studios
London N7 9AH UK
+44 (0) 207 993 2930
Katy.Turner@aquariusph.com

Proposed Approach
Problem: Existing diagnostics are either lab-based, slow or inaccurate
Solution: Rapidly deployable consumer molecular diagnostic based on isothermal
RPA-based amplification offering:
• Single copy-sensitivity
• Multiplexable
• Results in 15’
• High usability
• Low CoGs <€10
• Highly manufacturable
Partners sought: Engineering (mech & elec), clinical collaborators and KoLs
As part of Sapphiros KKR, Biocrucible has a strong financial footing
and capabilities in:
• Assay development & integration
• Protein manufacture
• Clinical & Regulatory
• Consumable manufacturing process
• Commercialisation & market access
• Initial Sars-CoV2 launch May 2022
Experience
20 years experience in device and drug development inc. C-level. Previous
experience of FP7 grants.
Biocrucible/Sapphiros team of ~30 scientists & industry leaders ex TwistDx, Alere and
Smith & Nephew.
Collaborations with leading academic sites in UK for initial Sars-CoV2 product
Partner status preferred
Dr David G Brooks
d.brooks@biocrucible.co.uk
+44 1223 792693
UK
PIC: 888432022
C1, D3 - Pandemic Preparedness

Proposed aaproach
Our scientific interests concern various aspects of cell biology. One of our
goals is to discover and study novel pathogenicity factors of UPEC
(uropathogenic Escherichia coli). We are also focused on elucidating
mechanisms that allow bacterial strains to survive in unfavorable conditions
(e.g., attack of the human immune cells), including studying the role of stress
response systems, which play an important role in controlling bacterial
survival. An important aspect is to deliver potential (including immune-
based) treatments for UPEC-mediated UTI.
We offer to provide a preclinical analysis of
potential anti-bug treatment tools/agents in
both in vitro and in vivo (mice) environments.
We have access to certified vivarium and
MGM laboratories to perform all necessary
analyses.
Organisation type – Academic
Experience
In our study we use both in vitro (tissue cultures) and in vivo (mice) UTI
models. We offer extensive expertise in molecular biology techniques,
including cloning, gene knock-out/replacement, mutagenesis, RNAseq, etc.
We collaborate closely with our NIEHS (USA) partners.
Members of our team previously gained experience at the National Institute
of Environmental Health Sciences (USA), Duke University (USA), UNAM
University (Mexico) and Institute of Bichemistry and Biophysics (Poland).
Role: Partner
Damian Gawel
Centre of Postgraduate Medical Education
Marymoncka 99/103
01-813 Warsaw,
Poland
Tel: +48 795-302-760
Email: damian.gawel@cmkp.edu.pl
Horizon Europe Tackling Diseases and Antimicrobial
Resistance (AMR)

Proposed Approach
Understanding of the problem
● Pandemics are not possible to predict but we can be more prepared
● Sentinel strategies to follow microorganismal genetic material should be
part of an inclusive pandemic alarm system
Part of the Scope to address
● Implementation of an Open database of expanding set of viral and bacterial
genetic markers.
● Proactive tracking of viral and bacterial genetic material.
● Using a variety of sample sources: environment, agricultural, community,
hospital.
Type of partners
● Partners with access to environmental, agricultural, community and hospital
settings.
Skills, capabilities, and facilities
● Molecular cloning, genotyping and phenotyping
● Management of complex synthetic biology
workflows
● Applied bioinformatics
● High throughput capabilities
Type of organisation and benefits
● We are part of an academic institution
● We do not work for profit
● We are under continuous methodological and
technological developmental and innovation
Experience
Previous, relevant, work or track record
● Extensive experience in biological engineering: six years of active work with
341 synthetic biology project carried out to completion.
Ability to attract the ‘Big Names’ in the sector (e.g. leading academics, major
thought leaders)
● Our umbrella institution, the University of Liverpool, is a big name in itself
● We can attract certain other higher education academic and industrial
Coordinator or Partner:
● Either. Depending on the skill sets and experience
of those involved
Contact details:
GeneMill, J. Enrique Salcedo-Sora, Manager,
synbio@liverpool.ac.uk, 0151 7946455,
United Kingdom
HORIZON-HLTH-2022-DISEASE-07-02 Pandemic Preparedness

Proposed Approach
What is your understanding of the part of the problem you can solve?
Regarding the topic we can assume clinic and recruitment WP
What part of the Scope do you want to address?
We can realize biomedical research and recruitment of patients regarding rare immunological
diseases (15)
If you are looking for partners, what type of partners are you looking for?
We are searching for a coordinator partner which is searching for a clinical partner in the field
of rare immunological diseases.
What skills, capabilities, facilities does your organisation
have that will be vital for this project?
• We have a big potential in recruiting patients since we
manage two hospitals.
• We have a diverse expertise when speaking about our
research groups.
• We can address all work packages related to the clinical
field in all of its phases and spheres.
We are part of the public Health Andalusian Service. In
this framework, IBIMA is the research Institute of Málaga
province, coordinating research and innovation of the
two main hospitals of the region.
Experience
We have previous experience in all the roles in H2020 projects.
We have cooperation's with the most important public bodies of Málaga (University of
Málaga, Council of Málaga, technological park of the city, and to different rare diseases
associations). Also, as we are part of Health Andalusian Service we can cooperate with support
infrastructures such as the Andalusian Network of design of advanced therapies, Centre of
genomic and oncologic research of Andalusia, biotechnology and nanotechnology Andalusian
centre, etc.. At European level we collaborate with partners such Nottingham University, Paul-
Ehrlich-Institute, university of Bournemouth and many more
We want to be a partner
Your contact details including:
Aitor Rando Rodán, aitor.rando@ibima.eu –
+34 686 39 21 74
Spain
Your organisation’s PIC: 998029218
HORIZON-HLTH-2022-DISEASE-06-04-two-stage - Development of
new effective therapies for rare diseases

Proposed Approach
Treatment of type 1 diabetes and
multiple sclerosis by increasing suppressive
function of gut immune system and blocking
autoimmunity.
Treg-binding protein coated nanoparticles containing
AhR ligand will be applied orally to induce Treg function.
Alternatively, genetically engineered plants that
overproduce AhR ligand will be used to make functional
food.
Looking for partners that can perform microbiota
and metabolomics analysis.
Animal breeding facility, zebra fish facility, Cell and
molecular biology units, Unit for cytometry (FACS
ARIA III sorter), Microscopy (confocal), Financial and
Administrative office, Research Management Unit,
IT sector.
IBISS is an academic organisation that entails vivid
scientific networking and stimulates cooperation
with international partners and provides full
logistic support. Overheads from the projects are
used to upgrade IBISS research facilities by
purchasing novel and high-cost equipment and for
training employees in state-of-the-art techniques.
Experience
1. Institute for Biological Research (IBISS), Serbia – experts in the pre-clinical evaluation of
potential therapeutics (animal models of autoimmune diseases, multi-parameter flow cytometry,
cell purification by sorting, immunoblot, RT-qPCR, fluorescent immunohistochemistry).
2. University of Ioaninna, Greece – experts in biochemical characterization of plant-derived
compounds and for synthesis of novel compounds with the required scaffolds.
3. ICREA & Institut Catala de Nanociencia i Nanotecnologia, Spain – experts in nanotechnology
4. University of Tours, France – experts in plant genetic engineering.
IBISS has a unique position in pre-clinical evaluation research area as it has in-house breeding
facility and strict, but rapid Ethical committee approval procedures for the animal usage.
We need help with Regulatory and Health Technology Assessment (HTA) strategy
I am planning to be a Coordinator.
Contact details:
Ivana Stojanović
ivana@ibiss.bg.ac.rs
+381600721372
Serbia
PIC 998386760
HORIZON-HLTH-2022-DISEASE-06-02-two-stage
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs
AhR
ligand
Specific
Treg-binding protein
AhR
Treg
OR
AhR-overexpressing
functional food
CNS
Pancreas

Proposed Approach
AMR (antimicrobial resistance) presents risks of becoming the next pandemic, with both direct and
indirect detrimental effects on the health of populations. By combining recent advances in
sequencing with a better understanding of the genetic determinants of AMR, I propose to develop
a real-time point-of-care diagnostic tool that can a) identify the microbial species responsible for
the infection and b) determine its antimicrobial resistance profile in under 4 hours (vs. the current
standard of 48 hours), directly from sputum or blood sample.
If successful, this proposal would revolutionize the current clinical management of (bacterial)
infectious disease, obviating the need for broad-spectrum antibiotics and improving outcomes.
This proposal addresses the “better methodologies and diagnostics that allow timely and accurate
diagnosis” part of the Scope. It can also be part of a larger proposal for an AMR-focused network.
My combined expertise in AMR, next-generation
sequencing (NGS) and machine learning (ML) makes
me an ideal contributor to a project on real-time
species identification and AMR diagnosis using NGS.
I seek partners with expertise in developing medical
diagnostics, especially in low-resource settings.
Imperial College London is an internationally
reputed academic institution and provides world-
class research support to its staff members.
Experience
I was the lead PI on several large-scale AMR grants in North America prior to moving to the UK.
I have long-standing connections with the World Health Organisation (WHO) and have worked with
several start-up companies in the field of diagnostics and AMR.
I was one of the leading scientists behind the development of the recently published WHO
catalogue of mutations associated with drug resistance in Mycobacterium tuberculosis, the world’s
largest infectious killer.
I am happy to be the Coordinator or a Partner.
Please don’t hesitate to contact me with your ideas:
Dr. Leonid Chindelevitch
lchindel@ic.ac.uk
+44-7389896780
Department of Infectious Disease Epidemiology
Imperial College London
United Kingdom
Pandemic Preparedness, AMR (Leonid Chindelevitch)

1. Proposed Approach
What part of the Scope do we want to address?
• Development and validation of novel diagnostics and countermeasures for virus
families of pandemic potential – specifically RNA viruses
• Development of standardised pre-clinical research assays and protocols
• Development of Precision biomarkers /diagnostics for virus families of pandemic
potential
• Partners with novel anti-viral targets to validate and exploit.
• Partners with novel therapeutics that require translational data
• Partners with novel rapid diagnostic technologies
2. Organisational Capabilities
What skills, capabilities, facilities does the Catapult have that will be vital
for this project?
• A Biosafety Level-3 (BSL3) national facility for research, testing and validation of new
diagnostics, biomarkers and innovative therapeutics for viruses with pandemic
potential
• BSL3 capabilities: Complex 3D cell models; cell sorting, live imaging, screening assays;
clinically relevant tissues and sample and pathogen strains
• Downstream bioanalysis for biomarker development / target validation / MOA
studies:
― spatial mass spec and spatial transcriptomics ; genomics; advanced
microscopy; integrated bioinformatics
MDC is an RTO - a not-for-profit organisation funded by the UK government and our
community. This financial independence allows us to operate at pace and scale.
3. Experience
What previous, relevant, work or track record do we bring to the team?
The MDC team have decades of experience in medicines research and translation.
Since 2018, MDC has:
• Participated in 160 partnered projects with 86 organisations across the UK
• Enabled partners working with MDC to raise over £50 million in new venture
investment
• Delivered the largest diagnostics laboratory testing project in UK history (SARS-CoV2)
Specific large pharma experience working with pandemic projects (PI on DARPA and
BARDA projects) for Influenza and SARS-CoV2, vaccines and therapeutics.
4. Administrative Information
Are you planning on being the Coordinator or a Partner?
Partner
Contact details:
Helen Bright
Head of Infection Biology
Medicines Discovery Catapult
Helen.bright@md.catapult.org.uk
HORIZON-HLTH-2022-DISEASE-07-02: Pandemic preparedness

Proposed Approach
Integrating synthetic chloride transporters and channels in therapies for chloride channelopathies
The exchange of anions between the living cell represents one of the most fundamental life-
sustaining phenomena, and many diseases are associated with defected chloride anion transport.
Hence, the design of synthetic anion transporters and channels is essential for treatment of
chloride channelopathies such as Best disease, Bartter's syndrome, Dent's disease, and cystic
fibrosis diseases. More specifically, we wish to tackle the problem of chloride channelopathies. Our
research has developed synthetic chloride transporters and artificial chloride channels that can be
the perfect candidates for channelopathies therapy and act as a valinomycin-like transporter, which
could be exploited in biomedical applications.
We are currently looking for collaborations to use these attractive synthetic anion transporters/
channels for in-vitro studies to transfer basic academic knowledge into more applied research. That
includes using them in vesicle assays, evaluating anion transport activity in cystic fibrosis (CF) cells
or other types of rare diseases, or integrating them as part of an artificial device that can mimic the
role of CLC channels in malfunctioning cells.
The Open University of Israel (OUI) has extensive
experience in EU collaborative projects where OUI
researchers have always held responsibilities as
WP leaders and Task leaders. European projects in
which the OUI has participated in the past include
FP6 and Horizon 2020 programs.
The Open University of Israel (OUI) is an academic
institute with many research activities.
The Research and Development Authority is
experienced with providing the financial
and administrative management for the research
activity and the space for disseminating results
in workshops and meetings and supporting
publication costs.
Experience
Our research group has developed a new family of cavitands named hetero-Bambusurils
(BUs), effective anion-binders, and have been used as a key component in designing synthetic
anion transporters. Hence, We have proven experience in organic synthesis and control chemical
modifications to afford the proper properties required from the transporters: hydrophobicity,
lipophilicity, water solubility, and degree of affinity binding to the target analyte. We are also
bringing knowledge on material characterization methods as well as skills in isolation and
purification processes.
This research has been presented in many scientific conferences, including the ICCBs and ISMSCs
and produced many collaborations within Europe (Prof. Hagan Bayley, Oxford University, UK and
Prof. Jurriaan Huskens, Twente University, Netherlands), Chinna (Prof. Jinqiu Liu, Jillin University)
and Australia (Prof. Philipe A. Gale, Sydney University).
I am planning on being a Partner and can act as a
WP Leader.
Prof. Ofer Reany
Department of Natural Science,
The Open University of Israel
E-Mail: oferre@openu.ac.il;
Mobile: +972-52-8310422
Organisation’s PIC: 998334477
HORIZON-HLTH-2022-DISEASE-06-04-two-stage:
"Development of New Effective Therapies for Rare Diseases"

Development of antimicrobial peptides (AMPs) based on toxins from toxin-antitoxin (TA) systems
We use toxins from bacterial TA systems as lead compounds for the development of antimicrobials
with novel mechanisms of action. Our work is, therefore, ideally suited to the upcoming
Therapeutics Call as part of JPIAMR.
What we can address
We observe that these TA system based peptides and our novel derivatives leads to potent
antimicrobials with hypothetically novel mechanisms of action. We have already shown that they
are active against AMR strains with MICs from the low micro molar to high nano molar range
depending on the bacterial strains and conditions of the assay.
Partners
We are looking for partners with complementary expertise. This includes: peptide chemists to
increase the range of derivatives we can explore in our assays, in vivo experts to guide formulation
and experimental setup in murine in vivo as well as to inform about selecting disease models and
commercial actors to guide our choices to expedite commercialisation.
Our strengths are in vitro testing of AMPs. This
includes MIC analysis (Mueller-Hinton / Whole
blood) across a broad range of bacterial species
(resistant and wt), hemolysis and human cell line
toxicity determination to calculated our probable
therapeutic window. Additionally, we calculate
propensity for resistance development amongst
many other assays.
We are an academic organisation interested in the
translation of our fundamental understanding of TA
systems to produce new antimicrobials. We
hypothesise that these novel leads will lead to
AMPs with novel mechanisms of action.
Experience
We have a long track record on working on characterisation and functional studies of DNA damage-
inducible TA systems from E. coli. Our translational activities have involved trying to harness the
toxicity of the toxins to produce AMPs. We have subsequently used our experience to expand the
number of toxins we are currently examining. We currently have peptides that are effective at high
nano-molar concentrations, peptides with no observable resistance development over the course
of the one month experiment as opposed to the antibiotic controls, peptides that are stable in
whole blood and resist the action of proteases.
We can act as both a coordinator or a partner
depending on the situation
James Booth
james.booth@rr-research.no
+47 41045852
Norway
JPIAMR Therapeutics - James Booth

Proposed Approach
What is your understanding of the part of the problem you can solve?
To make effective therapeutic vaccines
What part of the Scope do you want to address?
Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical
models, biomarker studies and new vaccine approaches from discovery to late stage development, from
bench-based research to clinical development of promising preventive candidates.
• Opportunities to use our platform
for novel vaccines – cancer immunotherapy
& infectious diseases
• Novel manufacturing for recombinant peptides
• Improved pre- and post-clinical testing
• Access to novel adjuvants
• Novel formulations
What skills, capabilities, facilities does your
organisation have that will be vital for this
project?
• Access to university laboratories
• Scientific knowledge – >25 years in
immunology
Is your organisation academic, SME, big
business, etc (and explain the benefits to this
project of whichever you are)
SME – offering a vaccine platform
technology that can accelerate new cancer
and disease vaccine development
Experience
What previous, relevant, work or track record can you bring to the team?
First OVM vaccine in Phase 1 Clinical Trial for cancer
Include your ability to attract the ‘Big Names’ in the sector (e.g. leading academics, major thought leaders)
Scientific Advisory Committee includes Professor Sir Andrew McMichael. Trial sites include UCLH,
Christie, Oxford, Velindre & Sarah Cannon.
CONFIDENTIAL INFORMATION
Are you planning on being the Coordinator or
a Partner? PARTNER
CONTACT DETAILS:
William Finch, CEO
E: wfinch@oxfordvacmedix.com
T: 00 44 (0)1865 784074
UK
PIC TBC
OXFORD VACMEDIX – Novel vaccine platform -Cluster 1 Destination 3

Proposed Approach
Understanding: To understand our ability to prepare for the AMR pandemic, we need to oversight
of ongoing & recent research activities and capabilities. In turn this will identify knowledge gaps
and areas of weakness and help to coordinate a trans-national approach.
Scope: Build a coordinated knowledge base of AMR research activities across EU & neighbouring
countries and how they contribute to AMR National Action Plans. In turn work out where to invest
effort for pandemic preparedness.
Partners: EU+ nationals who have oversight of their own NAPs to help draw together common
knowledge
Skills, capabilities, facilities: Scotland’s Rural College
(SRUC) has a range of expertise in agri-food
production from research to policy and human
health. SRUC has a track record for producing
academic, policy and industry relevant outputs.
Type: SRUC is a higher education academic &
research institution, > 1300 staff member, cover
whole Scotland.
Experience
Track record: I led a team to generate a register of AMR-related research activities associated with
Scotland over the last 5 years, and mapped them to the UK AMR NAP commitments. The project
took a One Health approach to cover all relevant sectors. My own expertise is in molecular
bacteriology, on transmission pathways of AMR and pathogenic bacteria.
Attract the ‘Big Names’: the team comprised stakeholders from all sectors including Scottish
Government; Scottish NHS; centres of expertise for animal epidemiology (EPIC) and water (CREW);
environmental protection agency (SEPA); food standards agency (FSS). Academic input covered
human health, animal health, plant health, water, wildlife and food. My own research is
internationally recognised, with large-scale grants, and well networked inc. EU COST Action.
My contribution: as a Partner
Contact details:
Prof. Nicola Holden
nicola.holden@sruc.ac.uk,
+44 1224711090
Aberdeen, Scotland, UK
SRUC PIC: 999899669
HORIZON-HLTH-2022-DISEASE-07-02 Pandemic preparedness

Proposed Approach
• Invasive fungal infections cause life-threatening infections in IC and critically ill patients
• High mortality rate and limited choice of antifungal drugs
• Urgent need to develop novel first-in-class therapies
• SBF has developed human antifungal antibodies with proven therapeutic efficacy in mouse
models - >80% improved survival and 3 log10 killing
• For our most advanced leads, target A is pan-fungal and target B is C. albicans specific
• Targets involved in stress response & do not have murine or human homologues
Project Scope
• Explore the possibility of pre-clinical development of the lead mAbs
• PK/PD studies, Immunogenicity and Biophysical characterisation, CMC and toxicity studies
• Join an existing consortium with European partners / new consortium
• Antibody discovery from human and immunised sources
• Extensive experience in antibody engineering and conducting
in vitro & ex-vivo characterisation
• Academic experts in medical mycology & fungal infection
biology (Prof C Munro, Aberdeen Fungal Group)
• Access to mouse infection models for PoC studies
• State-of-the-art microscopy, proteomics & flow cytometry
facilities
• Industry partner has a portfolio of products in preclinical and
clinical development
Our’s is a team of academics from the University of Aberdeen and
the SME partner Infex Therapeutics. Team members have a
strong track-record in successfully developing academic research
outputs into commercially viable products.
Experience
• We have developed a platform technology which can generate therapeutic human mAbs to
various fungal pathogens ( Patent protected)
• Scottish Biologics Facility is a leading recombinant antibody generation centre
• Several antibody leads in PoC animal models and immunodiagnostic development
(Alzheimer's Disease, Infectious diseases, liver fibrosis)
• Aberdeen Fungal Group has extensive experience studying fungal cell wall biosynthesis
and its role in pathogenesis
• Industry partner Infex therapeutics with expertise in anti-infectives drug discovery
Are you planning on being the Coordinator or a Partner?
Partner
Dr Soumya Palliyil
Head of Scottish Biologics Facility
University of Aberdeen
soumya.palliyil@abdn.ac.uk
What country are you from - UK
Your organisation’s PIC - 999929448
Horizon Europe
Tackling Disease and AMR – Cluster 1 Destination 3 and 5

Proposed Approach We have a consortia of Chemists, Materials Scientists, Microbiologists, Social Scientists
and Artificial Intelligence and Machine Learning specialists, interested in the development membrane active
antimicrobial technologies.
E.g. This patented technology platform has been shown to:
1. Morphing Multifunctional Material systems that undergo triggerable material changes from molecular
dimers, to spherical aggregates and hydrogel fibres while retaining biological activity;
2. antimicrobial agents and agents to increase/regenerate the efficacy of current antimicrobial agents.
Key publications: Chem. Sci. 2017, 8, 7620; J. Mat. Chem. B 2020, 8, 4694; ChemMedChem 2020, 15:22, 2193;
Molecules 2020, 25:18, 4126; RSC Adv., 2021, 11, 9550.
We are looking for partners to: (i) help apply and (ii) develop novel antimicrobial technologies to application.
My organisation is an acedemic
institution.
What we can offer:
• Access to SSA technology.
• Chemical synthesis facilities.
• Microbiology/Microscopy facilities.
• Patch clamp facilities.
• Assays to enable the study of
membrane:molecule interactions.
• Expertise in molecular association
and self-association.
Experience
In 2019 we launched an international network to support equality and diversity within the chemical sciences,
currently > 1,200 members: https://www.womeninsuprachem.com/ Angew. Chem. Int. Ed., 2021, 60, 11572.
We currently support consortia that has a line of site to the clinic, with over 30 active international members
supporting this effort, including individuals with expertise in data curation, artificial intelligence and machine
learning. This effort is further supported by UKHSA and industrial members.
We have developed consortia that have lead individual bids worth £20 million in the therapeutic sector and
included a 2021 Nobel prize winner.
We are happy to be either a Coordinator
or a Partner.
My contact details:
Name: Jennifer Hiscock
Email: J.R.Hiscock@Kent.ac.uk
Phone number: +44(0)1227 816467
Home country: UK
Institution: University of Kent
Novel molecular antimicrobial technologies
Your
Organisation
Logo / Brand

Proposed Approach
Speed up development of new vaccines against infectious diseases in humans.
Pre-clinical vaccine testing using in vitro human immune tissue model system
Partners: vaccine developers
Providing a lab vaccine testing
system/service for new vaccine
development.
University: academic& research
institution
Experience:
Using in vitro human immune tissue/cell culture system testing new vaccines, results closely relevant to humans
As a study Partner
Name: Dr Qibo Zhang
Email : qibo.zhang@liv.ac.uk
Phone: 0044 1517959677
UK
Using an in vitro human immune tissue culture system for new vaccine testing/development.
University of
Liverpool
Model advantages
• Both T cell immunity & antibody
responses
• Primary and memory responses
• Effect of pre-existing immunity
& age on response
• Close relevance to human in vivo
response
• A great system for testing
vaccines, & adjuvants

Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5

Similar to Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5 (20)

More from KTN

More from KTN (17)

Recently uploaded

Recently uploaded (20)

Horizon Europe Tackling Diseases and Antimicrobial Resistance (AMR) Webinar and Partnering - Cluster 1 / Destination 3 and 5